Kim et al., 2025 - Google Patents
In vivo mitochondrial base editing restores genotype and visual function in a mouse model of LHONKim et al., 2025
View HTML- Document ID
- 16287042454410594455
- Author
- Kim S
- Kim J
- Cha S
- Ju S
- Lim C
- Hong S
- Bae J
- Oh Y
- Jung S
- Kim S
- Shin H
- Yoon J
- Park J
- Ryou S
- Lim S
- Lee S
- Choi S
- Park S
- Choi C
- Choi M
- Kim L
- Park J
- Lee S
- Seo K
- Seong J
- Kim K
- Kim J
- Lee H
- Publication year
- Publication venue
- Nature communications
External Links
Snippet
Leber hereditary optic neuropathy (LHON), a maternally inherited mitochondrial disorder, results from point mutations in mitochondrial DNA (mtDNA), primarily affecting the MT-ND4 gene. To date, no animal model harboring authentic LHON mutations has been available …
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jang et al. | Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases | |
| Wang et al. | An inducible p21-Cre mouse model to monitor and manipulate p21-highly-expressing senescent cells in vivo | |
| Suzuki et al. | In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration | |
| Petrs-Silva et al. | Advances in gene therapy technologies to treat retinitis pigmentosa | |
| Uehara et al. | Start codon disruption with CRISPR/Cas9 prevents murine Fuchs’ endothelial corneal dystrophy | |
| Ahmad | CRISPR/Cas9—a promising therapeutic tool to cure blindness: current scenario and future prospects | |
| JP7712673B2 (en) | Methods for detecting, preventing, reversing, and treating neurological disorders | |
| Cwerman-Thibault et al. | Neuroglobin can prevent or reverse glaucomatous progression in DBA/2J mice | |
| Xi et al. | Gene augmentation prevents retinal degeneration in a CRISPR/Cas9-based mouse model of PRPF31 retinitis pigmentosa | |
| Yu et al. | Consequences of zygote injection and germline transfer of mutant human mitochondrial DNA in mice | |
| Repudi et al. | Neonatal neuronal WWOX gene therapy rescues Wwox null phenotypes | |
| Huang et al. | CRISPR-Cas9 generated Pompe knock-in murine model exhibits early-onset hypertrophic cardiomyopathy and skeletal muscle weakness | |
| Liu et al. | Gene therapy for retinitis pigmentosa: current challenges and new progress | |
| Nojima et al. | A point mutation in Semaphorin 4A associates with defective endosomal sorting and causes retinal degeneration | |
| Wu et al. | Heat-shock-induced tyrosinase gene ablation with CRISPR in zebrafish | |
| Tamura et al. | CRISPR activation for SCN2A-related neurodevelopmental disorders | |
| Meng et al. | In vivo genome editing via CRISPR/Cas9-mediated homology-independent targeted integration for Bietti crystalline corneoretinal dystrophy treatment | |
| Kumar et al. | Characterization of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina | |
| Furtado et al. | mRNA treatment rescues Niemann–Pick disease type C1 in patient fibroblasts | |
| Bouaita et al. | Downregulation of apoptosis-inducing factor in Harlequin mice induces progressive and severe optic atrophy which is durably prevented by AAV2-AIF1 gene therapy | |
| Bansal | Advances in retina genetics: Progress, potential, and challenges | |
| Fry et al. | Comparison of CRISPR-Cas13b RNA base editing approaches for USH2A-associated inherited retinal degeneration | |
| Niu et al. | FBLN2 is associated with Goldenhar syndrome and is essential for cranial neural crest cell development | |
| Du et al. | CRISPR/SaCas9-based gene editing rescues photoreceptor degeneration throughout a rhodopsin-associated autosomal dominant retinitis pigmentosa mouse model | |
| Mellen et al. | Development of an AAV-CRISPR-Cas9-based treatment for dominant cone-rod dystrophy 6 |